Search

APHQF - search results

If you're not happy with the results, please do another search

2 663
Marijuana-Stocks-Cannabis-plant-4

In the past year, the marijuana industry has been a monster in terms of growth. Many investors have decided to jump right in to this new industry with profits hitting all time highs. It is not out of the ordinary to see some marijuana stocks that have doubled or even tripled in value over the past 12 months.

With an industry that is expected to grow from around $5 billion to a whopping $17 billion by 2021, why not jump right in? Those numbers put the industry at a 300% legal sales growth with opportunities unexplored including new states legalizing the drug, organic growth within legal states, and the opportunity to move the black market into legal channels. The opportunity for marijuana is incredible. Here’s four stocks that have grown a substantial 10% in the last week.

1.Cara Therapeutics (+12.8%)
A market favorite for its large, quick, gains, Cara Therapeutics (NASDAQ: CARA) had unfortunately lost more than half of its market value in a two-week timeframe. Last week, Cara unexpectedly found its place and grew almost 13%.

One major piece of news seems to be the cause here. On July 12th Cara announced it data for its phase 1 trial of oral CR845, a treatment for pain and pruritus (itching) in patients with chronic kidney disease who are undergoing hemodialysis. All of the data was very promising.

2. Aphria (13.2%)
One of the Canadian giants in the industry, Aphria (NASDAQOTH: APHQF) had an exceptional week, growing over 13%. Many speculate that this is due to its fourth-quarter and full-year results for the fiscal year of 2017. The company did report a loss however in its fourth-quarter report but the $5.5 million is all accounted for in the companies new plans for expansion and growth. The largest strong spot of their report was a 25% decrease in all-in cash costs from 2016 to $1.31 a gram. As demand rises and costs fall, the company is expected to continue this growth trend.

3. Aurora Cannabis (+16.1%)
The largest gainer of the week among marijuana stocks with a 16% gain, was Aurora Cannabis (NASDAQOTH: ACBFF), yet another Canadian medical-cannabis producer. Aurora happens to be one of Aphria’s largest competitors. Aurora recently announced that it is in the process of developing what they call ‘the Aurora Sky project’. The project is essentially an 800,000 square foot facility that the company claims will be the most advanced and automated in the world. It is scheduled to be completed early next year.

One of the main reasons why Aurora skyrocket is an announcement that it would move from the TSX Venture Exchange to the much larger Toronto Stock Exchange. This move comes from a significant boost in the companies market cap over the past year, and could be just the jump investors need to get their feet wet.

0 1275
Marijuana-Stocks-weed money wad (1)

Towards the end of June, the S&P 500 had been up almost 20% over the course of 12 months. With a historical rise on average of around 7% annually, the new average is something investors are excited about. If this looks like solid gains than you’re right, but take a look at the gains for the marijuana industry and you’ll be ecstatic. In some instances this industry has doubled or even tripled its value over the past 12 months.

Why are these stocks doing so well? One of the main reasons behind it is the rapidly changing public opinion on the plant. With more research than ever being conducted, the public is learning the truth behind marijuana’s health benefits. A 2016 poll from Gallup showed that favorability toward the legalization of marijuana hit an all time high of over 60%. As opinions get better, so do sales. Investors project the sales from U.S. legal marijuana will top $6.9 billion in 2016 and are expected to more than triple by 2021. All of this leads to a bright future for cannabis related investments.

Marijuana stocks are more profitable than ever as sales continue to grow. This does not mean one should forgo their usual research, if anything one should be extra careful because it is a new industry. That said, this is the time to diversify a portfolio to get some green with some green. Here’s four stock picks that should see profit this year.

1. Aphria
This is one of many Canadian medical marijuana producers and retailers as the Canadian marijuana industry has been around for much longer than its U.S. counterpart (legally that is).

Aphria (NASDAQOTH: APHQF) has been profitable for investors for an astounding five consecutive quarters. A new project is seeing the company enlarging its growing capacity to a 1 million square feet to help produce an estimated 75,000 kilograms of cannabis per year.

2. Canopy Growth Corp.
Yet another Canadian marijuana stock; this company currently has the highest market cap. Canopy Growth Corp. (NASDAQOTH: TWMJF) is on track to be profitable for this year. This company has benefitted from exporting some of its production overseas in places where cannabis is legal medically.

Canopy Growth also acquired Mettrum Health (which boosted its customer reach within Canada). In addition, they recently purchased 472,000 sq. ft. for its headquarters to expand grow capacity.

3. MedReleaf
This is another profitable stock called MedRelead (NASDAQOTH: MEDFF) (TSX:LEAF), which was the largest North American IPO to date. MedReleaf, like Aphria and Canopy Growth is a producer of medical cannabis for Canadian patients. The company recently raised over $74 million dollars from its IPO to fund its expansion in a facility located in Bradford, Ontario. Once the new facility is completed, MedReleaf says it will be capable of 35,000 kilograms of annual cannabis production.

4.Scotts Miracle-Gro
This emerging marijuana stock Scotts Miracle-Gro (NYSE: SMG) is expected to generate high profits for the 2017 fiscal year. The majority of Scotts’ business comes from various traditional lawn and garden care products. The other portion of business comes from hydroponics. As the traditional part of Scotts’ sees various ups and downs according to weather etc., their hydroponics section is growing very quickly up 17% from last year.

0 4941
marijuana-stocks- benjamins

The marijuana industry is growing at a rapid pace, and investors have surely taken notice. Much more marijuana stocks have witnessed their valuations increase substantially, or maybe run even higher, over the trailing 12-month period.

Stemming from a 2016 Gallup poll and an April 2017 CBS News poll, the percentage of those who were receptive to seeing recreational cannabis legalized nationally which has surged to a respective 60% and 61%, both all-time highs. By comparison, Gallup’s 1995 poll showed just 25% approval for such a play, while the CBS News poll was a full 21-percentage-points lower just six years ago. The public wants change at the federal level, and investors are trying to beat that change by purchasing marijuana stocks.

The sale of legal marijuana has also risen. Investment firm Cowen & Co. is looking for $50 billion in legal annual cannabis sales by 2026, while a more recent report from Marijuana Business Daily implies that legal U.S. sales could triple between 2017 and 2021, to more than $17 billion. You’d probably struggle to find such consistent growth in any other industry or sector.

Which marijuana stock could hit $1 billion in sales first?

Yet, there are dozens of marijuana stocks to choose from, and they’re clearly not all going to be winners. The top performers, assuming marijuana remains legal in select states and that it gains broader approval in Canada and Mexico, are probably going to be the pot-based businesses that can really ramp up revenue and turn a healthy profit.

If there is a significant bench mark out there for marijuana stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry. But which marijuana stock has the best chance at being first to $1 billion in annual sales?

1. GW Pharmaceuticals
Considered the most sensible choice is cannabinoid-based drug developer GW Pharmaceuticals (NASDAQ: GWPH), which also happens to be the largest pot stock by a mile in terms of market cap.

What makes GW Pharmaceuticals so unique is its currently experimental cannabidiol therapy Epidiolex, which hit its primary endpoint in a pivotal phase 3 trials for two rare types of childhood-onset epilepsy. In both its Dravet syndrome and Lennox-Gastaut syndrome trials, Epidiolex led to a statistically significant reduction in seizure frequency compared to the placebo.

The success of these studies puts the company on track to get Epidiolex approved by the Food and Drug Administration (FDA), though nothing is ever a guarantee when it comes to the FDA. Assuming some potential for label expansion, Epidiolex could very well hit $1 billion in peak annual sales, if not a tad higher.

2. Corbus Pharmaceuticals
Corbus Pharmaceuticals (NASDAQ: CRBP) is considerably more of a wildcard than GW Pharmaceuticals, but if one specific clinical trial goes its way, it could easily leap to $1 billion in annual sales.

Corbus’ pipeline consists of a solitary drug known as anabasum, which is a synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptors expressed on immune cells and fibroblasts. Its drug is being tested in four indications, but one stands out head and shoulders above the rest: cystic fibrosis (CF). There are few drugs to treat CF, and most that are FDA approved target a very specific mutation, making their impact limited within the CF community. Anabasum is believed to have a global anti-inflammatory effect, meaning it could be taken by most, or all, CF patients.

3. Canopy Growth Corp.
Another seemingly logical marijuana stock that could thrive is Canopy Growth Corp. (NASDAQOTH: TWMJF), a producer and retailer of medical cannabis products and oils in Canada. Medical weed has been legal in Canada since 2001.

Canopy Growth has been a busy bee of late on the acquisition front. It completed its acquisition of Mettrum Health earlier this year, and it acquired a 472,000 square foot facility that includes its current corporate headquarters.

Growth by acquisition gives the company immediate access to more medical marijuana patients and the ability to rapidly expand its growing capacity.

4. Aphria
One of Canopy Growth’s largest competitors in the Canadian medical marijuana producing and retail business is Aphria (NASDAQOTH: APHQF). Aphria has the distinction of being the most prominently profitable marijuana stock, with the company reporting five consecutive quarterly profits.

Unlike Canopy Growth, Aphria is doing things organically. It’s been funding expansions of its existing grow capacity, and is currently working on its most aggressive growth initiative to date, Phase IV.

5. Aurora Cannabis
And how can we forget Aurora Cannabis (NASDAQOTH: ACBFF), yet another of Canada’s medical cannabis producers and retailers. Aurora Cannabis has lagged its peers in recent profits due to its expansion-based spending.

Like Aphria, Aurora Cannabis is all about organic development. Aurora Cannabis has touted its Aurora Sky project, which will increase its cultivating capacity nearly ninefold, as the most technologically advanced and automated cannabis-grow facility in the world, when completed.

0 790

MassRoots Receives US$450,000 in Proceeds from Early Exercise of Warrant by Aphria

“Aphria remains one of our most well-capitalized and highest-caliber partners and we are thankful for their continued support by fully exercising their warrants,” stated MassRoots CEO Isaac Dietrich. “As a technology platform, MassRoots is available in every state and country that regulates the production of cannabis and these warrant proceeds will greatly assist in increasing our market share of cannabis consumers and businesses.”

“We’re committed to continuing to build a robust portfolio of cannabis-infrastructure investments by backing innovate companies like MassRoots,” stated Aphria CEO Vic Neufeld. “MassRoots has the potential to be the leading technology platform in the cannabis sector and we look forward to continuing to foster a close relationship between our companies.”

About MassRoots
MassRoots is one of the largest technology platforms for the regulated cannabis industry. The Company’s mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. For more information, please visit MassRoots.com/Investors.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sellers of medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first publicly licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, the growth of MassRoots’ business, the growth of Aphria’s business, potential partnerships, new features, related business strategies, statements with respect to internal expectations, estimated margins, expectations for future growing capacity, the expected growth of production facilities in North America, any commentary related to the legalization of marijuana and the timing related thereto, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria or MassRoots to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

0 3471
marijuana-stocks-cannabis-canadian_flag

The Canadian cannabis industry may have received the catalyst it needed…

Yesterday, CBC News reported that the Liberal government will announce legislation next month that will legalize marijuana in Canada by July 1, 2018.

This is a huge announcement as it was one of the main reasons why Justin Trudeau and the Liberal Party won the Canadian general election in 2015.

CBC said it learned that the legislation will be announced during the week of April 10th and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan.

A Change of Words

According to the CBC, Parliamentary Secretary to the Minister of Justice Bill Blair briefed the Liberal caucus on the roll-out plan and the legislation during caucus meetings this weekend.

This is a big change from early March when Blair said the Canadian government will take as much time as it needs to correctly implement a legal recreational cannabis program. Blair previously did not suggest a specific time frame because he said it could vary from province-to-province and territory-to-territory

An Industry to Watch

The Canadian medical cannabis industry continues to record double-digit percentage growth on a month-over-month basis and has more than 100,000 patients. There are currently 38 federally licensed medical cannabis producers in Canada and we are favorable on the opportunity that these companies have on hand.

We are favorable on this update and expect to see the market rally higher off this news. Some companies investors should watch include: Cronos Group (MJN.V) (PRMCF), Emblem Corp (EMC.V) (EMMBF), OrganiGram (OGI.V) (OGRMF), Canopy Growth (WEED.TO) (TWMJF), Aphria (APH.V) (APHQF), Aurora Cannabis (ACB.V) (ACBFF), and VinergyRes (VIN.CN) (VNNYF).

Authored by: Michael Berger

 

Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. An affiliate of MAPH Enterprises LLC owns 43,500 shares of EMBLEM as well as 21,750 Warrants

PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER (http://marijuanastocks.com/content/terms-and-conditions-use/)

0 2856
Marijuana-Stocks- cannabis-trump

On Thursday, Press Secretary Sean Spicer said the President understands the value of medical cannabis for those in need, however, recreational cannabis or adult-use is an issue for the Department of Justice to provide further clarification.

Spicer seemed to link marijuana use to the opioid addiction crisis plaguing the United States. Despite his un-educated attempt to link cannabis use to opioid addiction, a Johns Hopkins report published in August 2014 determined that states with legal marijuana programs have fewer prescription overdose deaths.

In January 2017, the National Academies of Sciences, Engineering and Medicine also released a review of 10,000 medical cannabis studies published since 1999. These data associated with these studies provide substantial evidence that supports the use of cannabis or its extracts for the treatment of chronic pain.

In November 2015, Forbes Magazine reported about a 60-Minutes episode that blamed the opioid crisis entirely on big pharmaceutical companies.

Cannabis advocates need to continue make their voices heard by respective state and local officials and legislatures to push back on this.

Stocks Under Pressure

Over the last few months, we have de-risked our leverage to the United States cannabis industry while increasing leverage to Nasdaq-traded biotech companies and Canadian cannabis companies.

We continue to remain favorable on the United States cannabis industry but expect to see weakness in the near-term and continue to focus on Canadian traded cannabis stocks as well as the biotech leaders.

Stocks we are watching and remain most favorable on include: GW Pharmaceuticals (GWPH), Emblem Corp (EMC.V) (EMMBF), Kush Bottles (KSHB), Canopy Growth (TWMJF) (WEED.TO), Zynerba Pharmaceuticals (ZYNE), Aphria (APHQF), Reliq Health (RQHTF) Aurora (ACBFF), VPR Brands (VPRB), Lexaria (LXRP), VinergyRes (VIN.CN), and Canabo Medical (CMM.V) (CAMDF).

0 5716

@WolfOfWeedST

With the Trump Administration in complete disarray and touting debunked information about Cannabis & Opioid connections we at MarijuanaStocks.com decided to play a little game of devils advocate. The fact remains that the Trudeau administration remains progressive and is doing what all governments should be doing i.e. listening to its people. Canadians are in overwhelming support of legal cannabis markets which is why they legalized medical marijuana last year. This year the country plans on legalizing recreational use in an effort to crush black markets, create jobs, industry and position itself as a worldwide leader in cultivation. With a completely legal market Canada will face one major issue that will reap major benefits to public cultivation companies. That issue being one of supply and demand. Already operating at a deficit and coupled with an approval process by Health Canada that can take years we foresee investors sending their capital north of the border unless they are invested in companies insulated by restrictions on the recreational markets. Those US companies being: Construction for Cultivation, manufacturers of products, companies monetizing industrial Hemp’s many uses, CBD manufacturers, technology & media services (like us).

One of the highly anticipated events of 2017 is the tabling of legislation as it relates to a legal recreational cannabis program in Canada. This development is expected to take place in the Spring.

During December, a federal task force released its long-awaited recommendations relating to the legalization of recreational marijuana. The report was prepared by a committee comprised of nine members who have worked together since June.

All Eyes on Legislation this Spring

When Canada legalizes recreational marijuana, demand is going to increase significantly, however it will take time for the program to be up and running. For this reason, Canadian licensed medical cannabis producers have been aggressively raising capital to make acquisitions and to increase production capacity.

One of the largest fundamental changes within the Canadian cannabis sector over the last year relates to the amount of capital entering the industry as well as the source of the capital. The capital entering the industry is not only larger but smarter too; these investors and firms are long-term holders that see the bigger picture.

Five Opportunities to Watch

The Canadian cannabis industry has continued to be a bright spot for cannabis investors and 2017 has already provided investors with strong investment returns.

This sub-sector of the cannabis industry has been on fire since July 2016 and the increased interest has been fueled by anticipation of Canada becoming the first G-7 nation to legalize recreational cannabis.

Although the Canadian cannabis industry offers investors a lot of opportunity, it does not come without risk. Many of the companies levered to this sector have seen a significant rally over the last six months while some have not fared as well.

We want highlight five Canadian cannabis stocks that should be on every investors radar. From

The Green Organic Dutchman’s second round of financing closes today at 5pm and investors can still reach out to support@sbpartners.io if they still want to access this opportunity.

Terms of the offering are as follows: The company is selling units at $1.15 CAD per unit and the minimum purchase level is 5,000 units. Each unit consists of one common share and one full share purchase warrant. Each warrant provides the investor to purchase shares of The Green Organic Dutchman at $2.15 for the next two-years no matter what price the shares are trading at.

The Green Organic Dutchman produces farm grown pharmaceutical grade organic cannabis. The company has differentiated itself from the competition by producing high-quality organic cannabis that sells for a higher price and has better profit margins. The company is led by a management team that has a proven track record of success with licensed Canadian medical cannabis producers such as OrganiGram and Emblem Corp.

Aphria (APH.V: TSX Venture) (APHQF: OTC) has been one of the top performers this year and the shares are up approximately 30% YTD. The shares moved considerably higher after the company received conditional approval to up-list on the TSX exchange and we remain favorable on the company’ long-term outlook.

In early February, Aphria announced a $50 million private placement at $5.00 a share and this transaction is expected to close this week. The company expects that 80% of the net proceeds will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated towards strategic investments.

The Part IV expansion will increase Aphria’s capacity from 300,000 to 1 million square feet. In addition, the company’s infrastructure will grow to over 250,000 square feet which is necessary to service the expected 70,000 kilograms of eventual annualized harvests. The project includes 700,000 square feet of Dutch style greenhouses, 230,000 square feet of infrastructure, including new Level 9 vaults, automation for all the greenhouses, processing areas, warehouse facilities, a 15 MW power and heat co-generation facility and security consistent with ACMPR standards.

Aphria anticipates completion of Part IV within 12 months, Health Canada approvals within 4 months of completing the expansion and first harvest within 4 months after such approvals.

In December 2016, Aphria invested $8.4 million in Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF: OTC) at $1.40 a share. Canabo is another stock we are very favorable as the shares trade at an almost 40% discount to the level at which Aphria invested at.

Canabo owns and operates the largest line of medical cannabis clinics in Canada and we expect to see the company continue to expand its footprint across Canada.

CMM.V is trading at $0.85 after the shares rallied more than 13% on above-average volume. We highlighted the company last month as an attractive opportunity and continue to see upside to current levels. The company’s United States symbol, CAMDF is trading below $0.67 after a 16.4% rally and we continue to see upside to these levels.

PharmaCan Capital (MJN: TSX Venture) (PRMCF: OTC) has the top performing licensed Canadian medical cannabis producer this year and the shares are up 92.6% YTD. The company does business as Cronos Group and in 2016, it sold one of its properties to NYSE-traded Innovative Industrial Properties (IIPR).

The shares were under pressure last week after the company announced a $15 million private placement at $2.25 a share. MJN.V quickly bounced back and rallied more than 40% over the few trading days.

The company’s wholly-owned subsidiary, In The Zone, recently received approval from Health Canada to sell medical cannabis. This comes while its other wholly-owned subsidiary, Peace Naturals is positioned to capitalize on the recent medical cannabis legislation in Germany through its export relationship with Pedanios GmbH.

Although the shares have recent run significantly higher, we have become increasingly favorable on the company over the last quarter and continue to monitor trading closely. Become a Technical420 Premium Member to keep up with our analysis.

Canopy Growth Corp. (WEED.TO: TSX) (TWMJF: OTC) continues to be the Canadian medical cannabis leader and we view the company as one of the best long-term cannabis investments.

The company recently completely the acquisition of Mettrum Health, which significant expanded its product line and led to a surge in revenue. The market did not initially respond favorable to Canopy earnings report and the shares recorded its largest drop of the year.

During the quarter, Canopy Growth recorded $3 million in net income off $9.8 million in revenue and total revenue increased 15% when compared to the prior quarter and 180% when compared to the same period last year.

During the quarter, the company sold 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram, up from 462 kilograms at an average price of $7.34 per gram during the prior year period.

The company recorded strong growth on pretty much all metrics and as of December 31st , Canopy Growth reported to have over 29,000 registered patients which is more than 260% higher than the number of patients as of December 31, 2015.

Canopy has recaptured most of its losses and we continue to remain favorable and monitor trading activity closely. WEED.TO recently traded into the $13.20 range and the shares are currently trading at $12.64. We remain favorable on Canopy Growth and this company should be on every cannabis investor radar screen.

Marijuana-Stocks-Cannabis-3

The best Marijuana Stocks / Cannabis Stocks to Watch in 2017 & Beyond.

Earlier this year we covered the market for marijuana stocks post Trump and many of these marijuana stocks have continued to see progress over the time since. Now that we’re finally through the transitional period, it’s time to look ahead at marijuana stocks to watch in 2017 and even beyond. Who would have thought this industry would have come this far, let alone open up the doors to an entirely new and evolving sector.

In fact, according to new research, North American sales are projected to top $20.2 billion by 2021. Marijuana sales in North America grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a report from Arcview Market Research. So, it’s hard not to find the best marijuana stocks to watch this year and in the years to come.  Several we have watched, mentioned, reported on, and reviewed very recently with favorable market activity in play.

First and foremost, mCig, Inc. (MCIG) is a company we’ve watch grow immensely over the last few months.  Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on really building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”
The Green Organic Dutchman Holdings Ltd. (TGOD) comes onto this list following the roll-out of our previous coverage on now public company, Emblem Corp (EMMBF). Emblem was one of the most anticipated offerings that has come out of Canada in the last few months.  For TGOD, besides being licensed under the access to cannabis for medical purposes regulations (ACMPR) to cultivate medical marijuana, TGOD has some big names behind it from a financing front including familiar faces from the Emblem & Organigram camps.

In addition to this, the company has 1,000 kg current annual indoor operating capacity as well as a newly acquired property coming in at 75 acres, which adjoins the current facility. The planned IPO of TGOD is in October, more details here.

We looked at OWC Pharmaceutical Research Corp.  (OWCP).  This was trading around $0.95 and recent trading activity has seen this hit as high as $3.23.  The company has most recently been adding to its advisory board.  Both Dr. Sharon Rozenblat and Ms. Miriam Sani, MSc Eng. Dr. Rozenblat will be overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016 and Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. The company itself focuses on two things: 1. medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines and 2. OWCP is developing unique delivery systems for the effective delivery and dosage of medical cannabis.

Rocky Mountain High Brands (RMHB) is another company we’ve watched since the days it was called Totally Hemp Crazy and ever since, we’ve seen this company grab attention of the market.  The company specialized in hemp infused beverages and more recently an alkaline water called Eagle Spirit, which was issued a trademark on Feb 22. Aside from this, the company has been implementing a partnership strategy, enhancing its internal fulfillment operations, as well as making it a known presence at industry conventions.  As of Wednesday 2-22-2017, shares of Rocky Mountain High had hit highs of $0.118.

Advantis Corp. (ADVT) was a company we started watching last summer and since the beginning of the year, we picked back up on it.  There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF) made our list a few months ago and it has kept its spot especially considering the move for Canada’s legalization. The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. In addition to partnership and collaboration deals with the like of companies like Radient Technologies (RTI.V), this company has also obtained significant financial contributions through its bought deal private placement with a syndicate of underwriters led by Canaccord Genuity Corp. for aggregate gross proceeds to Aurora of $60,007,500.

Other Canadian marijuana stocks to watch include Canopy Growth (WEED.TO), which just announced that it has entered into a memorandum of understanding with Namaste Technologies Inc. “to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis.”

Namaste’s database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly. Namaste also has 26 e-commerce retail stores in 20 countries. We watch now in the midst of all of the developments as Canopy has grown from a stock trading under $3 to today’s price of more than $12/share.

Future Farm (CSE: FFT) (OTCQB: FFRMF) formerly AGSTF, this company is something we’ve covered from very early on.  This company has been aggressively expanding into the marijuana space.  The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment.  We began following this at $0.137 and this week it has managed to hit highs of $0.50; a solid run of 265% so far and could certainly be something to be watching into 2017.

Similar to Aurora, Aphria, Inc. (APH.V) (APHQF) has entered into an agreement with Clarus Securities to which the Underwriters have agreed to purchase, on a “bought deal” basis, 10,000,000 Common Shares of the Company at a price of C$5.00 per Common Share for aggregate gross proceeds to the Company of C$50,000,000. This is expected to close on or about February 24 of this year. The company also recently received approval to jump from the TSX Venture Exchange to list on the TSX and depending on meeting certain conditions, is expected to be finalized on or before the TSX imposed May 3rd, 2017 deadline. The stock on the US exchange and the Canadian exchange has been on an uptrend since last March.

1 7929
marijuana-stocks-cannabis-canadian_flag

Canadian licensed medical cannabis producers built off the momentum from Wednesday and benefited from this as it carried into Thursday’s trading session.

These movements are significant because several of these stocks were under pressure on Tuesday and early Wednesday (post-Canopy Growth earnings).

Investors should keep an eye on how this sub-sector continues to trade as we believe it is comprised of some of the highest quality opportunities for investors.

We recapped some of these recent price movements and provided our updated thesis below:

Canopy Growth Corp (WEED.TO: TSX) (TWMJF: OTC) recaptured most of its losses from Tuesday after the shares rallied 3.7% on above-average trading volume. We continue to view Canopy Growth as one of the top long-term cannabis investments due to its leading position in the Canadian medical cannabis market. Canopy Growth recently broke below the $10 level and investor should keep an eye on shares as we continue to see long-term upside to current levels.

OrganiGram Holdings (OGI.V: TSX Venture) (OGRMF: OTC) saw a nice rally yesterday and we will monitor how this continues today. OGI and OGRMF rallied more than 5% and this was a nice change from the recent trend. We will provide updates on any significant price movements today. Stay tuned as we continue to hold cautiously.

Emblem Corp. (EMC.V: TSX Venture) (EMMBF: OTC) continued to rally yesterday and the shares were one of the top performers as they also rallied more than 5%. EMC is trading at $4.17 while EMMBF trades near $3.20. We continue to hold as we are favorable on the long-term outlook. Emblem has a lock up coming up in March and we have started to receive questions about this. Although we expect this to cause a short-term dip, we do not expect it to last long and will keep an eye on any significant price movements leading up to this.

Aurora Cannabis (ACB.V: TSX Venture) (ACBFF: OTC) ended the day up less than 2% and we continue to hold onto the shares. We have contemplated exiting this position and re-entering on weakness, however, we have not decided yet. The reason why we are questioning this holding is due to valuation. When you look at Aurora’s fully-diluted market cap, it is over $1 billion which is significant. We view the risk-reward scenario as balanced here and will keep you updated on how the shares move from here.

Aphria (APH.V: TSX Venture) (APHQF: OTC) edged lower yesterday and this move followed an 18% rally over the last week. APHQF traded as high as $5.15 before ending the day at $4.97 and We continue to see upside to current levels but we may trim the size of our position because of the strength of the recent rally.

CanniMed Therapeutics (CMED.TO: TSX) is trading at $11.95 after the shares edged slightly higher yesterday and we are on the sidelines at current levels. Although we are favorable on the company’s recent execution, the exchange it trades on, and its business model; we are cautious at these levels. We will keep you updated on how the shares trade from here

Cronos Group (MJN.V) recaptured all its losses from Wednesday as the shares rallied approx. 8% yesterday. MJN.V is trading at $2.59 and we are on the sidelines at current levels. We were favorable on MJN after Wednesday’s dip and will monitor how the shares respond today. The company announced a bought deal this week at $2.25 a share and this has caused the shares to trade a little more volatile over the last two trading sessions.

0 4038

Although the Canadian cannabis market has seen incredible growth over the last year, we believe there is a lot of room to run as the legislation to create a recreational cannabis program is scheduled to be introduced this spring.

When looking at growth catalysts for companies levered to the Canadian medical cannabis market, none is more significant than the legalization of recreational cannabis at the federal level. At the United Nations meeting earlier this year, Health Minister Jane Philpott said Canada’s Liberal Party government will introduce a law in the spring to legalize recreational cannabis.

Some Producers to Benefit More than Others

Although recreational cannabis will benefit all licensed producers that are approved to distribute cannabis, some will benefit more than others.

Many licensed producers have been expanding and constructing new facilities to prepare for the increased demand. Investors should focus on companies that are well capitalized, well positioned and well managed.

Private opportunities like The Green Organic Dutchman have generated great interest from investors as the company possesses one of the largest licensed land lots in Canada as well as one of the most attractive valuations when compared to its peers.

This is different than the approach taken by Aphria (APHQF), a licensed producer that recently acquired 200 acres in a separate location in Canada. This acquisition though, is not as attractive as that of The Green Organic Dutchman since Aphria’s property will require its own license from Health Canada.

Companies are Positioning Themselves for Growth

According to Health Canada, if a licensed medical cannabis producer acquires a property that is adjacent to its licensed facility, it does not need to receive a new license.

If the property in not attached or adjacent to the cannabis producer’s licensed property, it will need to apply for and receive a new license from Health Canada.

Although legal recreational cannabis represents a huge market in Canada, these companies must scale the size of their operations to fully capitalize on this opportunity.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements